Drugs / AMDC-GIR
AMDC-GIR
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02838316 | May 2017 → Dec 2026 expected | disorder of pharynx | Peter Belafsky, MD | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05421689 | May 2022 → Dec 2026 expected | disorder of pharynx | University of California, Davis | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMDC-GIR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02838316 ↗ |
| Known as | Autologous Muscle Derived Cells for Gastro-Intestinal Repair | “The purpose of this double-blind, randomized, placebo-controlled, multicenter clinical trial is to evaluate the safety and efficacy of Autologous Muscle Derived Cells for...” NCT05421689 ↗1“Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR)” NCT02838316 ↗ |
| Modality | Cell therapy | “Autologous muscle cell therapy” NCT02838316 ↗ |
| Route | Intramuscular | “Intramuscular injection of AMDC-GIR” NCT02838316 ↗ |